Karimi Fereshte, Mosadeghrad Ali Mohammad, Vaezi Mohammad, Janbabaei Ghasem, Ghobeishipour Hoda, Nozarian Mohammad Hussein, Mousavi Seyed Asadollah, Fumani Hossein Kamranzadeh, Rad Soroush, Barkhordar Maryam, Shiraji Sahar Tavakoli, Ghavamzadeh Ardeshir, Yaghmaie Marjan
Research Center for Emergency and Disaster Resilience, Red Crescent Society of the Islamic Republic of Iran, Tehran, Iran.
Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
BMC Health Serv Res. 2025 Aug 18;25(1):1094. doi: 10.1186/s12913-025-13251-1.
Stem cell transplantation (SCT) is a crucial treatment for various blood disorders and cancers. This procedure involves the transfer of healthy stem cells to replace damaged or diseased cells, restoring healthy blood cell production and alleviating symptoms. This study aimed to calculate the total cost of SCT at Shariati Hospital, Tehran, Iran.
A retrospective cross-sectional design was employed, analyzing data from 143 SCT patients admitted between August 2022 and March 2023. Activity-Based Costing (ABC) was utilized to allocate costs across combined operational centers, encompassing intermediate clinical support and patient care units. Cost data were extracted from hospital financial records and analyzed using SPSS and Excel in 2024.
Patients had a mean age of 39 years and an average hospital stay of 27.2 days. The mean total cost per patient was 2,166,904,089 IRR (approximately $51,594 USD), equivalent to 24,232 international dollars based on Purchasing Power Parity (PPP) adjustment. Direct medical costs constituted 49% of total expenses, with overhead costs comprising 51%. Human resources accounted for the largest cost components, notably physicians (38.8%) and nursing staff (13.8%). Government subsidies covered 54.1% of direct costs, followed by out-of-pocket payments (13.9%) and basic insurance (12.8%).
Stem cell transplantation imposes a substantial financial burden on the healthcare system in Iran. These findings underscore the urgent need for policy interventions to optimize resource allocation, establish standardized tariffs, and implement mechanisms that improve access and provide financial protection for patients.
干细胞移植（SCT）是治疗各种血液疾病和癌症的关键疗法。该程序涉及转移健康干细胞以替代受损或患病细胞，恢复健康血细胞生成并缓解症状。本研究旨在计算伊朗德黑兰沙里亚蒂医院干细胞移植的总成本。
采用回顾性横断面设计，分析2022年8月至2023年3月期间收治的143例干细胞移植患者的数据。运用作业成本法（ABC）在包括中级临床支持和患者护理单元的联合运营中心之间分配成本。成本数据从医院财务记录中提取，并于2024年使用SPSS和Excel进行分析。
患者的平均年龄为39岁，平均住院时间为27.2天。每位患者的平均总成本为2,166,904,089伊朗里亚尔（约合51,594美元），根据购买力平价（PPP）调整后相当于24,232国际美元。直接医疗成本占总费用的49%，间接费用占51%。人力资源占成本的最大组成部分，尤其是医生（38.8%）和护理人员（13.8%）。政府补贴覆盖了54.1%的直接成本，其次是自付费用（13.9%）和基本保险（12.8%）。
干细胞移植给伊朗的医疗系统带来了巨大的经济负担。这些发现强调了迫切需要采取政策干预措施，以优化资源分配、制定标准化收费标准，并实施改善患者就医机会和提供财务保护的机制。
